Outcomes of Neoadjuvant Chemotherapy for Invasive Intraductal Papillary Mucinous Neoplasm Compared with de Novo Pancreatic Adenocarcinoma

Alessandro Fogliati,Andrea Zironda,Guido Fiorentini,Stella Adjei,Abdelrahman Amro,Patrick P. Starlinger,Travis E. Grotz,Susanne G. Warner,Rory L. Smoot,Cornelius A. Thiels,Michael L. Kendrick,Sean P. Cleary,Mark J. Truty

DOI: https://doi.org/10.1245/s10434-023-14875-5

IF: 4.339

2024-02-06

Annals of Surgical Oncology

Abstract:Abstract Background The management of invasive intraductal papillary mucinous cystic neoplasm (I-IPMN) does not differ from de novo pancreatic ductal adenocarcinoma (PDAC); however, I-IPMNs are debated to have better prognosis. Despite being managed similarly to PDAC, no data are available on the response of I-IPMN to neoadjuvant chemotherapy. Methods All patients undergoing pancreatic resection for a pancreatic adenocarcinoma from 2011 to 2022 were included. The PDAC and I-IPMN cohorts were compared to evaluate response to neoadjuvant therapy (NAT) and overall survival (OS). Results This study included 1052 PDAC patients and 105 I-IPMN patients. NAT was performed in 25% of I-IPMN patients and 65% of PDAC patients. I-IPMN showed a similar pattern of pathological response to NAT compared with PDAC ( p = 0.231). Furthermore, positron emission tomography (PET) response (71% vs. 61%; p = 0.447), CA19.9 normalization (85% vs. 76%, p = 0.290), and radiological response (32% vs. 37%, p = 0.628) were comparable between I-IPMN and PDAC. A significantly higher OS and disease-free survival (DFS) of I-IPMN was denoted by Kaplan–Meier analysis, with a p -value of < 0.001 in both plots. In a multivariate analysis, I-IPMN histology was independently associated with lower risk of recurrence and death. Conclusions I-IPMN patients have a longer OS and DFS after surgical treatment when compared with PDAC patients. The more favorable oncologic outcome of I-IPMNs does not seem to be related to early detection, as I-IPMN histological subclass is independently associated with a lower risk of disease recurrence. Moreover, neoadjuvant effect on I-IPMN was non-inferior to PDAC in terms of pathological, CA19.9, PET, and radiological response and thus can be considered in selected patients.

oncology,surgery

What problem does this paper attempt to address?

### The Problem the Paper Attempts to Solve

This paper aims to compare the pathological response and overall survival (OS) and disease-free survival (DFS) of invasive intraductal papillary mucinous neoplasm (I-IPMN) with primary pancreatic ductal adenocarcinoma (PDAC) after neoadjuvant chemotherapy. The main objective of the study is to evaluate whether the efficacy of neoadjuvant chemotherapy in I-IPMN patients is similar to that in PDAC patients and to explore whether I-IPMN has a better prognosis.

#### Research Background
- The management of I-IPMN is usually the same as that of PDAC, but there is currently a lack of data on the response of I-IPMN to neoadjuvant chemotherapy.
- Although I-IPMN is considered to have a better prognosis, its response to neoadjuvant therapy compared to PDAC is not yet clear.

#### Main Findings
- Among patients who underwent surgical resection, the OS and DFS of I-IPMN patients were significantly better than those of PDAC patients.
- The pathological response, CA19.9 levels, PET response, and imaging response of I-IPMN patients after neoadjuvant chemotherapy were similar to those of PDAC patients.
- Multivariate analysis showed that the histological characteristics of I-IPMN were independently associated with a lower risk of recurrence and death.

#### Conclusion
- The OS and DFS of I-IPMN patients after surgical treatment were significantly longer than those of PDAC patients.
- The effect of neoadjuvant chemotherapy on I-IPMN is not inferior to that on PDAC, with similar pathological response, CA19.9 levels, PET response, and imaging response. Therefore, neoadjuvant chemotherapy can be considered for selectively high-risk I-IPMN patients.